title: Cysteinyl Leukotrienes and Their Receptors: Emerging Therapeutic Targets in Central Nervous System Disorders.
abstract: Cysteinyl leukotrienes are a group of the inflammatory lipid molecules well known as mediators of inflammatory signaling in the allergic diseases. Although they are traditionally known for their role in allergic asthma, allergic rhinitis, and others, recent advances in the field of biomedical research highlighted the role of these inflammatory mediators in a broader range of diseases such as in the inflammation associated with the central nervous system (CNS) disorders, vascular inflammation (atherosclerotic), and in cancer. Among the CNS diseases, they, along with their synthesis precursor enzyme 5-lipoxygenase and their receptors, have been shown to be associated with brain injury, Multiple sclerosis, Alzheimer's disease, Parkinson's disease, brain ischemia, epilepsy, and others. However, a lot more remains elusive as the research in these areas is emerging and only a little has been discovered. Herein, through this review, we first provided a general up-to-date information on the synthesis pathway and the receptors for the molecules. Next, we summarized the current findings on their role in the brain disorders, with an insight given to the future perspectives.
authors.affiliation: Laboratory for Alzheimer's Disease and Related Disorders, Department of Pharmacology, China Pharmaceutical University, Nanjing, China.|Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University, Nanjing, China.
authors.forename: Arijit
authors.identifier: 0000-0001-6408-749X
authors.initials: A
authors.lastname: Ghosh
authors.affiliation: Laboratory for Alzheimer's Disease and Related Disorders, Department of Pharmacology, China Pharmaceutical University, Nanjing, China.|Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University, Nanjing, China.
authors.forename: Fang
authors.initials: F
authors.lastname: Chen
authors.affiliation: Department of Biomedical Sciences, City University of Hong Kong, Hong Kong SAR, China.
authors.forename: Abhimanyu
authors.initials: A
authors.lastname: Thakur
authors.affiliation: Laboratory for Alzheimer's Disease and Related Disorders, Department of Pharmacology, China Pharmaceutical University, Nanjing, China.|Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University, Nanjing, China.
authors.forename: Hao
authors.initials: H
authors.lastname: Hong
mesh_terms: D016718:Arachidonic Acid / Q000378:metabolism; D002493:Central Nervous System Diseases / Q000378:metabolism* / Q000628:therapy; D003545:Cysteine / Q000378:metabolism*; D006801:Humans; D015289:Leukotrienes / Q000378:metabolism*; D008954:Models, Biological; D018077:Receptors, Leukotriene / Q000378:metabolism*
chemical_list: D015289:Leukotrienes; D018077:Receptors, Leukotriene; C112381:cysteinyl-leukotriene; D016718:Arachidonic Acid; D003545:Cysteine; C083169:leukotriene D4 receptor
keywords: Alzheimer's disease; Cerebral ischemia; Cysteinyl leukotrienes type 1 receptor; G-protein-coupled receptor 17; Multiple sclerosis